Weaver C. Barksdale & Associates, Inc. Bristol Myers Squibb CO Transaction History
Weaver C. Barksdale & Associates, Inc.
- $109 Million
- Q1 2024
A detailed history of Weaver C. Barksdale & Associates, Inc. transactions in Bristol Myers Squibb CO stock. As of the latest transaction made, Weaver C. Barksdale & Associates, Inc. holds 21,121 shares of BMY stock, worth $854,344. This represents 1.05% of its overall portfolio holdings.
Number of Shares
21,121
Previous 21,369
1.16%
Holding current value
$854,344
Previous $1.1 Million
4.47%
% of portfolio
1.05%
Previous 1.07%
Shares
10 transactions
Others Institutions Holding BMY
# of Institutions
2,553Shares Held
1.49BCall Options Held
25.9MPut Options Held
20M-
Vanguard Group Inc Valley Forge, PA186MShares$7.53 Billion0.2% of portfolio
-
Black Rock Inc. New York, NY163MShares$6.58 Billion0.21% of portfolio
-
State Street Corp Boston, MA91.6MShares$3.7 Billion0.23% of portfolio
-
Jpmorgan Chase & CO New York, NY88.8MShares$3.59 Billion0.44% of portfolio
-
Capital International Investors Los Angeles, CA70.2MShares$2.84 Billion0.79% of portfolio
About BRISTOL MYERS SQUIBB CO
- Ticker BMY
- Exchange NYSE
- Sector Healthcare
- Industry Drug Manufacturers—General
- Shares Outstandng 2,126,160,000
- Market Cap $86B
- Description
- Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple my...